Navigation Links
Senesco Technologies, Inc. Announces Management Change
Date:11/16/2009

NEW BRUNSWICK, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that, on November 16, 2009, Bruce C. Galton resigned from his position as a member of the board of directors. In addition, Mr. Galton resigned from his positions as the Company's President and Chief Executive Officer to pursue other interests. Mr. Galton and the Company currently are discussing the terms of Mr. Galton's separation with the Company.

On November 16, 2009, the Board of Directors appointed Jack Van Hulst, a current member of the Board of Directors, to serve as the Company's President and Chief Executive Officer.

Bruce Galton commented, "My goal has been to bring Senesco's Factor 5A technology to the clinic to determine its utility to treat multiple myeloma, a serious bone marrow cancer. The Company is poised to initiate its pivotal toxicology study to support an IND application. It has been an honor and a pleasure to bring the Company to this point."

Harlan Waksal, M.D., Senesco's Chairman, commented, "We wish Bruce well with his future endeavors, and we look forward to having Jack as our new President and Chief Executive Officer. I will continue to play an active role with the Company. The Board, management and all employees remain excited about the future of the Company."

Additional details regarding the foregoing are disclosed on the Company's Form 8-K filed today.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability to successfully transition to new management; the ability of the Company to consummate additional financings; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE Senesco Technologies, Inc.


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference
2. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
3. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
4. ArborGen and Senesco Announce Wood Quality Results
5. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
6. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
7. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
8. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
10. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
11. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell Therapeutics ... technologies for neurodegenerative diseases, announced today that Chaim Lebovits ... Regenerative Medicine,s (ARM) 5 th Annual Cell & Gene ... EDT in Boston . In ... Officer & Chief Operating Officer, will participate in a panel ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... Labs . The move comes after the company changed focus to making analytical ... new brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 A ... Opportunity Analysis and Industry Forecast, 2014-2022 ," the global market was valued at ... registering a CAGR of 9.6% from 2016 to 2022. ... ...      (Logo: ...
(Date:4/18/2017)... Switzerland (PRWEB) , ... April 18, 2017 , ... ... smartphone/tablet app that converts conductivity readings to concentration levels and vice-versa. , One ... chemistry is analyzing solution strength in concentration control or monitoring. The principle of ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):